This article was originally published in The Gray Sheet
Executive SummaryBegins distribution of its Cadence V-110 implantable cardioverter-defibrillator following Aug. 8 approval of the PR 1500 Cadence Programmer. The V-110 was approved via a PMA supplement in June, but full release of the device was dependent upon approval of the Cadence Programmer. The biphasic, tiered- therapy defibrillator weighs 15% less than the current Cadence V- 100, and is priced at $18,900
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.